Geneos Wealth Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Geneos Wealth Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25	Closed	-$1K	–	2500
2018 Q3	$1K	Hold	25	–	–	﹤0.01%	2385
2018 Q2	$1K	Hold	25	–	–	﹤0.01%	2234
2018 Q1	$1K	Hold	25	–	–	﹤0.01%	2142
2017 Q4	$1K	Hold	25	–	–	﹤0.01%	2144
2017 Q3	$1K	Hold	25	–	–	﹤0.01%	2095
2017 Q2	$1K	Hold	25	–	–	﹤0.01%	2045
2017 Q1	$2K	Buy	+25	New	+$1.86K	﹤0.01%	1938

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geneos Wealth Management's EGRX Position: Q4 2018 in Review

Geneos Wealth Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 25 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in EGRX in Q1 2017 and held it in 7 quarters. The position peaked at $2K in Q1 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Geneos Wealth Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Geneos Wealth Management sold 25 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1K.
Geneos Wealth Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Geneos Wealth Management's Eagle Pharmaceuticals, Inc. position peaked at $2K in Q1 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Geneos Wealth Management's 13F filing for Q4 2018, filed 7 Sep 2021.